Response to: Comments on The Impact of Aprepitant on Nausea and Vomiting Following Laparoscopic Sleeve Gastrectomy: A Blinded Randomized Controlled Trial

Obes Surg. 2024 Aug;34(8):3121-3122. doi: 10.1007/s11695-024-07403-1. Epub 2024 Jul 20.

Authors

Manuel A Guerrero¹, Elías Ortiz², Alberto I González², Valeria Jaime², José A Guzmán², Isaac Esparza², José O Orozco², Almino Ramos², Carlos Zerrweck³

Affiliations

¹ Anesthesiology Department, Baja Hospital, Ernesto Sarmiento 2308, Burócrata, Ruiz Cortines, 22046, Tijuana, B.C Tijuana, BCN, Mexico.
² Bariatric Surgery Department, Baja Hospital, Ernesto Sarmiento 2308, Burócrata, Ruiz Cortines, 22046, Tijuana, B.C Tijuana, BCN, Mexico.
³ Bariatric Surgery Department, Baja Hospital, Ernesto Sarmiento 2308, Burócrata, Ruiz Cortines, 22046, Tijuana, B.C Tijuana, BCN, Mexico. [email protected].

PMID: 39030291
DOI: 10.1007/s11695-024-07403-1

No abstract available

Publication types

Letter

MeSH terms

Antiemetics* / therapeutic use
Aprepitant* / therapeutic use
Gastrectomy* / adverse effects
Humans
Laparoscopy*
Morpholines / therapeutic use
Obesity, Morbid* / surgery
Postoperative Nausea and Vomiting* / prevention & control
Randomized Controlled Trials as Topic

Substances

Aprepitant
Antiemetics
Morpholines